{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:25:56Z","timestamp":1789053956706,"version":"build-2803163510"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>The DONATE HCV trial demonstrated the safety and efficacy of transplanting hearts from hepatitis C viremic (HCV+) donors. In this report, we examine the cost-effectiveness and impact of universal HCV+ heart donor eligibility in the United States on transplant waitlist time and life expectancy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We developed a microsimulation model to compare 2 waitlist strategies for heart transplant candidates in 2018: (1) status quo (SQ) and (2) SQ plus HCV+ donors (SQ + HCV). From the DONATE HCV trial and published national datasets, we modeled mean age (53 years), male sex (75%), probabilities of waitlist mortality (0.01\u20130.10\/month) and transplant (0.03\u20130.21\/month) stratified by medical urgency, and posttransplant mortality (0.003\u20130.052\/month). We assumed a 23% increase in transplant volume with SQ + HCV compared with SQ. Costs (2018 United States dollar) included waitlist care ($2200\u2013190 000\/month), transplant ($213 400), 4-wk HCV treatment ($26 000), and posttransplant care ($2500\u201311 300\/month). We projected waitlist time, quality-adjusted life-years (QALYs), lifetime costs, and incremental cost-effectiveness ratios (ICERs [$\/QALY, discounted 3%\/year]; threshold \u2264$100 000\/QALY).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Compared with SQ, SQ + HCV decreased waitlist time from 8.7 to 6.7 months, increased undiscounted life expectancy from 8.9 to 9.2 QALYs, and increased discounted lifetime costs from $671 400\/person to $690 000\/person. Four-week HCV treatment comprised 0.5% of lifetime costs. The ICER of SQ + HCV compared with SQ was $74 100\/QALY and remained \u2264$100 000\/QALY with up to 30% increases in transplant and posttransplant costs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Transplanting hearts from HCV-infected donors could decrease waitlist times, increase life expectancy, and be cost-effective. These findings were robust within the context of current high HCV treatment costs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000004378","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T21:00:09Z","timestamp":1671224409000},"page":"961-969","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["The Cost-effectiveness of Transplanting Hearts From Hepatitis C-infected Donors Into Uninfected Recipients"],"prefix":"10.1097","volume":"107","author":[{"given":"Ann E.","family":"Woolley","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA."},{"name":"Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya R.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Jones","sequence":"additional","affiliation":[{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane J.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari R.","family":"Mallidi","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA."},{"name":"Division of Thoracic and Cardiac Surgery, Department of Surgery, Brigham and Women\u2019s Hospital, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Givertz","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA."},{"name":"Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA."},{"name":"Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep R.","family":"Mehra","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA."},{"name":"Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"and Anne M.","family":"Neilan","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA."},{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA."},{"name":"Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA."},{"name":"Division of General Academic Pediatrics, Department of Pediatrics, Massachusetts General Hospital, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics-2019 update: a report from the American Heart Association.","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cardfail.2015.04.013","article-title":"Advanced (stage D) heart failure: a statement from the heart failure society of America guidelines committee.","volume":"21","author":"Fang","year":"2015","journal-title":"J Card Fail"},{"issue":"Suppl 2","key":"R4-20250604","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/ajt.15278","article-title":"OPTN\/SRTR 2017 annual data report: heart.","volume":"19","author":"Colvin","year":"2019","journal-title":"Am J Transplant"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1053-2498(03)00148-7","article-title":"Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation.","volume":"23","author":"Haji","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1001\/jama.296.15.1843","article-title":"Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients.","volume":"296","author":"Gasink","year":"2006","journal-title":"JAMA"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1056\/NEJMc1802706","article-title":"The drug-intoxication epidemic and solid-organ transplantation.","volume":"378","author":"Mehra","year":"2018","journal-title":"N Engl J Med"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1111\/ajt.13971","article-title":"Improving organ utilization to help overcome the tragedies of the opioid epidemic.","volume":"16","author":"Goldberg","year":"2016","journal-title":"Am J Transplant"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa1812406","article-title":"Heart and lung transplants from HCV-infected donors to uninfected recipients.","volume":"380","author":"Woolley","year":"2019","journal-title":"N Engl J Med"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.healun.2019.08.010","article-title":"The impact of using hepatitis c virus nucleic acid test-positive donor hearts on heart transplant waitlist time and transplant rate.","volume":"38","author":"Gernhofer","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"R11-20250604","article-title":"HCV positive allograft use in heart transplant is associated with increased access to overdose donors and reduced waitlist mortality without compromising outcomes.","author":"Altshuler","journal-title":"J Card Fail"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/ajt.16245","article-title":"Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients.","volume":"21","author":"Logan","year":"2021","journal-title":"Am J Transplant"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.healun.2021.09.002","article-title":"Cost-effectiveness and system-wide impact of using hepatitis C-viremic donors for heart transplant.","volume":"41","author":"Wayda","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/ajt.15054","article-title":"Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy.","volume":"18","author":"Gupta","year":"2018","journal-title":"Am J Transplant"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold.","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"R17-20250604","first-page":"1015","article-title":"Heart transplantation, adult recipients.","volume":"38","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.athoracsur.2020.05.163","article-title":"Long-term survival after heart transplantation: a population-based nested case-control study.","volume":"111","author":"Suarez-Pierre","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/EDE.0000000000000472","article-title":"Assessment of heart transplant waitlist time and pre- and post-transplant failure: a mixed methods approach.","volume":"27","author":"Goldstein","year":"2016","journal-title":"Epidemiology"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jacc.2016.05.082","article-title":"Wait-list outcomes for adults with congenital heart disease listed for heart transplantation in the U.S.","volume":"68","author":"Alshawabkeh","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"e005276","DOI":"10.1161\/CIRCHEARTFAILURE.118.005276","article-title":"Current use of hearts from hepatitis c viremic donors.","volume":"11","author":"Moayedi","year":"2018","journal-title":"Circ Heart Fail"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"l223","DOI":"10.1136\/bmj.l223","article-title":"Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population-based cohort study.","volume":"364","author":"Taylor","year":"2019","journal-title":"BMJ"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/jocs.12857","article-title":"Perioperative mortality is the Achilles heel for cardiac transplantation in adults with congenital heart disease: Evidence from analysis of the UNOS registry.","volume":"31","author":"Shah","year":"2016","journal-title":"J Card Surg"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.healun.2011.10.017","article-title":"Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation.","volume":"31","author":"Moreno","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCHEARTFAILURE.113.000807","article-title":"Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure.","volume":"7","author":"Long","year":"2014","journal-title":"Circ Heart Fail"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.healun.2013.10.017","article-title":"Overall quality of life improves to similar levels after mechanical circulatory support regardless of severity of heart failure before implantation.","volume":"33","author":"Grady","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jchf.2016.09.008","article-title":"Cost-effectiveness of left ventricular assist devices in ambulatory patients with advanced heart failure.","volume":"5","author":"Baras Shreibati","year":"2017","journal-title":"JACC Heart Fail"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.resuscitation.2019.03.021","article-title":"Cost effectiveness and quality of life analysis of extracorporeal cardiopulmonary resuscitation (ECPR) for refractory cardiac arrest.","volume":"139","author":"Dennis","year":"2019","journal-title":"Resuscitation"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.resuscitation.2018.03.036","article-title":"Health related quality of life after extracorporeal cardiopulmonary resuscitation in refractory cardiac arrest.","volume":"127","author":"Spangenberg","year":"2018","journal-title":"Resuscitation"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1524-4733.2008.00425.x","article-title":"Utility estimates for decision-analytic modeling in chronic heart failure\u2013health states based on New York Heart Association classes and number of rehospitalizations.","volume":"12","author":"G\u00f6hler","year":"2009","journal-title":"Value Health"},{"key":"R33-20250604","first-page":"88","article-title":"A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention.","volume":"6","author":"Gregory","year":"2013","journal-title":"Am Health Drug Benefits"},{"key":"R34-20250604","article-title":"Trends in utilization, mortality, major complications, and cost after total artificial heart implantation in the United States (2009-2015).","author":"Briasoulis","journal-title":"Hellenic J Cardiol"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jtcvs.2013.09.033","article-title":"Resource use trends in extracorporeal membrane oxygenation in adults: an analysis of the Nationwide Inpatient Sample 1998-2009.","volume":"148","author":"Maxwell","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R36-20250604","first-page":"1446","article-title":"Health care costs for patients with heart failure escalate nearly 3-fold in final months of life.","volume":"22","author":"Obi","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"R38-20250604","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJM199808063390606","article-title":"Gains in life expectancy from medical interventions\u2013standardizing data on outcomes.","volume":"339","author":"Wright","year":"1998","journal-title":"N Engl J Med"},{"key":"R39-20250604","doi-asserted-by":"crossref","first-page":"e003221","DOI":"10.1161\/JAHA.116.003221","article-title":"Cost-effectiveness of Ivabradine for heart failure in the United States.","volume":"5","author":"Kansal","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R40-20250604","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13124","article-title":"Cost-utility analysis of direct ventricular assist device vs double bridges to heart transplantation in patients with refractory heart failure.","volume":"31","author":"Chang","year":"2017","journal-title":"Clin Transplant"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.healun.2020.03.004","article-title":"Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: an ISHLT expert consensus statement.","volume":"39","author":"Aslam","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/tri.12184","article-title":"Can donors with high donor risk indices be used cost-effectively in liver transplantation in US transplant centers?","volume":"26","author":"Kensinger","year":"2013","journal-title":"Transpl Int"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cgh.2018.08.042","article-title":"Cost effectiveness of transplanting HCV-infected livers into uninfected recipients with preemptive antiviral therapy.","volume":"17","author":"Bethea","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R44-20250604","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.14929","article-title":"Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients.","volume":"18","author":"Kadatz","year":"2018","journal-title":"Am J Transplant"},{"key":"R45-20250604","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.healun.2021.01.1919","article-title":"Long-term outcomes in heart and lung transplants from HCV-viremic donors to uninfected recipients: the DONATE HCV trial.","volume":"40","author":"Woolley","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"R46-20250604","doi-asserted-by":"crossref","first-page":"e014495","DOI":"10.1161\/JAHA.119.014495","article-title":"Outcomes of adult heart transplantation using hepatitis C-positive donors.","volume":"9","author":"Kilic","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"R47-20250604","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/jamacardio.2019.4748","article-title":"Expanding heart transplant in the era of direct-acting antiviral therapy for hepatitis C.","volume":"5","author":"Schlendorf","year":"2020","journal-title":"JAMA Cardiol"},{"key":"R48-20250604","article-title":"A clinical and cost-effectiveness analysis of the HeartMate 3 left ventricular assist device for transplant-ineligible patients: a United Kingdom perspective.","author":"Lim","journal-title":"J Heart Lung Transplant"},{"key":"R49-20250604","doi-asserted-by":"crossref","first-page":"e1002032","DOI":"10.1371\/journal.pmed.1002032","article-title":"Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis.","volume":"13","author":"Iyengar","year":"2016","journal-title":"Plos Med"},{"key":"R50-20250604","doi-asserted-by":"crossref","first-page":"e12972","DOI":"10.1111\/tid.12972","article-title":"Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.","volume":"20","author":"Mansour","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"R51-20250604","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/apt.16508","article-title":"Systematic review: hepatitis C viraemic allografts to hepatitis C-negative recipients in solid organ transplantation.","volume":"54","author":"Raasikh","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"R52-20250604","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamacardio.2020.0692","article-title":"Use of temporary mechanical circulatory support for management of cardiogenic shock before and after the united network for organ sharing donor heart allocation system changes.","volume":"5","author":"Varshney","year":"2020","journal-title":"JAMA Cardiol"},{"key":"R53-20250604","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40472-015-0052-y","article-title":"The cost of transplant immunosuppressant therapy: is this sustainable?","volume":"2","author":"James","year":"2015","journal-title":"Curr Transplant Rep"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:12:29Z","timestamp":1749060749000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004378","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,27]]}}}